CW Advisors LLC Boosts Stake in Zoetis Inc. $ZTS

CW Advisors LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 1.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 85,739 shares of the company’s stock after purchasing an additional 1,104 shares during the period. CW Advisors LLC’s holdings in Zoetis were worth $14,113,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Wormser Freres Gestion lifted its holdings in shares of Zoetis by 1.9% in the 1st quarter. Wormser Freres Gestion now owns 46,050 shares of the company’s stock valued at $7,538,000 after purchasing an additional 843 shares during the last quarter. Sandhill Capital Partners LLC lifted its holdings in shares of Zoetis by 0.6% in the 1st quarter. Sandhill Capital Partners LLC now owns 93,849 shares of the company’s stock valued at $15,452,000 after purchasing an additional 600 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its position in Zoetis by 47.1% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 5,778 shares of the company’s stock worth $951,000 after acquiring an additional 1,851 shares during the period. GM Advisory Group LLC lifted its position in Zoetis by 6.9% during the 1st quarter. GM Advisory Group LLC now owns 2,298 shares of the company’s stock worth $378,000 after acquiring an additional 149 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its position in Zoetis by 1,250.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 48,986 shares of the company’s stock worth $8,066,000 after acquiring an additional 45,359 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $202.43.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $155.4950 on Friday. The business’s fifty day moving average price is $154.00 and its two-hundred day moving average price is $158.75. The stock has a market cap of $68.91 billion, a PE ratio of 26.76, a price-to-earnings-growth ratio of 2.52 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter last year, the firm earned $1.56 earnings per share. The business’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.